Ventrix

Founded in 2013, Ventrix is a private, preclinical-stage biotech pioneering ECM-based biotherapeutics. The company's core hypothesis is that delivering tissue-specific extracellular matrix can restart stalled repair processes by providing the essential architectural and biochemical framework for cellular regeneration. Targeting significant unmet needs in cardiovascular repair, Ventrix aims to translate the fundamental biology of the ECM into a new therapeutic modality. As a pre-revenue company, its success hinges on advancing its lead programs through clinical validation.

Proprietary platform for sourcing, processing, and formulating tissue-specific extracellular matrix (ECM) to create biotherapeutics that provide structural and biochemical cues to guide endogenous tissue repair and regeneration.

Ventrix competes in the cardiovascular regenerative space against cell therapy companies (e.g., Mesoblast, CardioCell), gene therapy approaches, and device-based solutions. Its differentiation lies in targeting the tissue microenvironment (ECM) rather than delivering cells or genes directly. It also faces competition from other ECM/biomaterial companies like ACell and Matricelf in broader regenerative applications.